non-small cell lung cancer (NSCLC) - Articles and news items

AstraZeneca’s lung cancer drug receives full approval in the EU

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

The EC has granted full marketing authorisation for AstraZeneca’s Tagrisso for the treatment of mutation-positive non-small cell lung cancer (NSCLC)…

Novartis’ lung cancer drug combination receives EU approval

Industry news / 5 April 2017 / Niamh Marriott, Junior Editor

The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat fnon-small cell lung cancer…

AstraZeneca lung cancer drug receives FDA approval

Industry news / 4 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) to treat non-small cell lung cancer (NSCLC)…

Novartis receives positive CHMP opinion for lung cancer combination

Industry news / 27 February 2017 / Niamh Marriott, Digital Editor

The EMA approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with non-small cell lung cancer…

Novartis’ NSCLC study shows 16.6 month progression-free survival

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo…

FDA approves Roche’s immunotherapy assay to support treatment decisions in lung cancer

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC) who may benefit from treatment […]

OncoGenex’s Phase 3 non-small cell lung cancer trial did not meet primary endpoint

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

OncoGenex’ results, analysed from the Phase 3 trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial…

NICE says CDF case for nivolumab to treat lung cancer is not clear cut

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer…

Scancell preparing SCIB2 for clinical study in lung cancer

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor…

Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients 

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+